PRECISION BIOSCIENCES INCDTIL決算レポート
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
DTIL Q4 2025 Key Financial Metrics
売上高
$34.2M
粗利益
N/A
営業利益
$12.5M
純利益
$20.1M
粗利益率
N/A
営業利益率
36.6%
純利益率
58.9%
前年比成長
5261.1%
EPS
$2.62
資金フロー
PRECISION BIOSCIENCES INC Q4 2025 財務サマリー
PRECISION BIOSCIENCES INC reported revenue of $34.2M (up 5261.1% YoY) for Q4 2025, with a net profit of $20.1M (up 213.5% YoY) (58.9% margin). Cost of goods sold was N/A.
主要財務指標
| 総売上高 | $34.2M |
|---|---|
| 純利益 | $20.1M |
| 粗利益率 | N/A |
| 営業利益率 | 36.6% |
| 報告期間 | Q4 2025 |
PRECISION BIOSCIENCES INC 年度売上推移
PRECISION BIOSCIENCES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $34.3M). Click any linked year to see what changed vs the prior 10-K.
PRECISION BIOSCIENCES INC 四半期売上・純利益の履歴
PRECISION BIOSCIENCES INC quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 四半期 | 売上高 | 売上前年比 | 純利益 | 純利益率 |
|---|---|---|---|---|
| Q4 2025 | $34.2M | +5261.1% | $20.1M | 58.9% |
| Q3 2025 | $13.0K | -97.7% | $-21.8M | -167476.9% |
| Q2 2025 | $18.0K | -100.0% | $-23.5M | -130666.7% |
| Q1 2025 | $29.0K | -99.8% | $-20.6M | -70913.8% |
| Q4 2024 | $638.0K | -90.9% | $-17.7M | -2781.3% |
| Q3 2024 | $576.0K | -95.6% | $-16.4M | -2851.6% |
| Q2 2024 | $49.9M | +152.2% | $32.7M | 65.6% |
| Q1 2024 | $17.6M | +100.3% | $8.6M | 48.8% |
損益計算書
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 売上高 | $17.6M | $49.9M | $576000 | $638000 | $29000 | $18000 | $13000 | $34.2M |
| 前年比成長 | 100.3% | 152.2% | -95.6% | -90.9% | -99.8% | -100.0% | -97.7% | 5261.1% |
貸借対照表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 総資産 | $184.7M | $165.8M | $153.3M | $136.4M | $124.4M | $108.9M | $93.5M | $154.4M |
| 総負債 | $147.5M | $91.1M | $88.4M | $80.0M | $75.1M | $74.9M | $76.9M | $62.2M |
| 株主資本 | $37.2M | $74.7M | $64.9M | $56.4M | $49.3M | $34.1M | $16.6M | $92.2M |
キャッシュフロー
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 営業CF | $-19.0M | $-14.9M | $-5.9M | $-18.7M | $-19.1M | $-20.3M | $-15.3M | $-11.3M |